Factors Associated With Symptomatic Interstitial Lung Disease in Patients With Systemic Sclerosis (SSc-ILD)

被引：0
|
作者：
Chaichatpornsuk, V. [1 ]
Teerapuncharoen, K. [1 ]
Muangchan, C. [1 ]
机构：
[1] Siriraj Hosp, Dept Med, Bangkok, Thailand
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2024年 / 209卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1834
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)-The LOTUSS study
    Khanna, Dinesh
    Albera, Carlo
    Fischer, Aryeh
    Seibold, James
    Raghu, Ganesh
    Khalidi, Nader
    Chung, Lorinda
    Schiopu, Elena
    Chen, Dan
    Gorina, Eduard
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [22] HEALTHCARE RESOURCE UTILIZATION AND ASSOCIATED COSTS OF PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE (PF-ILD) AND SYSTEMIC SCLEROSIS ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) IN FRANCE.
    Nasser, M.
    Rabiega, P.
    Boussel, L.
    Si-Mohamed, S.
    Barbet, V
    Marque, S.
    Massol, J.
    Revel, D.
    Thivolet-Bejui, F.
    Chalabreysse, L.
    Maucort-Boulch, D.
    Jouneau, S.
    Hachulla, E.
    Cottin, V
    VALUE IN HEALTH, 2020, 23 : S717 - S718
  • [23] Mediators of systemic sclerosis-associated interstitial lung disease (SSc-ILD): systematic review and meta-analyses
    Fields, Aislin
    Potel, Koray N.
    Cabuhal, Rhandel
    Aziri, Buena
    Stewart, Iain D.
    Schock, Bettina C.
    THORAX, 2023, 78 (08) : 799 - 807
  • [24] Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Interim Analysis of SENSCIS-ON
    Glaeser, S.
    Allanore, Y.
    Vonk, M. C.
    Azuma, A.
    Mayes, M. D.
    Gahlemann, M.
    James, A.
    Kohlbrenner, V
    Stowasser, S.
    Highland, K. B.
    PNEUMOLOGIE, 2021, 75 : S26 - S27
  • [25] NOCEBO EFFECT ON DIARRHOEA REPORTED IN THE SENSCIS TRIAL OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)
    Distler, O.
    Highland, K.
    Azuma, A.
    Miede, C.
    Alves, M.
    Sfikakis, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1457 - 1457
  • [26] Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) and Organ Damage: Data from the SENSCIS Trial
    Pope, Janet
    Proudman, Susanna
    Stevens, Wendy
    Henes, Joerg
    Simonovska, Rozeta
    Alves, Margarida
    Allanore, Yannick
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 3025 - 3027
  • [27] Examining Clinical Characteristics of Patients with Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) and Myositis Antibodies: A Retrospective Case Series
    Pandya, K.
    Raddawi, M.
    D'Silva, K. M.
    Montesi, S. B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [28] Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Interim Analysis of SENSCIS-ON
    Allanore, Yannick
    Vonk, Madelon
    Azuma, Arata
    Mayes, Maureen
    Gahlemann, Martina
    James, Alexandra
    Kohlbrenner, Veronika
    Stowasser, Susanne
    Highland, Kristin
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [29] BASELINE CHARACTERISTICS OF PATIENTS WITH IMPROVEMENT OR PROGRESSION OF SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) DURING THE SENSCIS TRIAL
    Hoffmann-Vold, A. M.
    Hachulla, E.
    Herrick, A.
    Moua, T.
    Riemekasten, G.
    Vonk, M.
    James, A.
    Alves, M.
    Distler, O.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 720 - 720
  • [30] Effect of Nintedanib in Patients with Systemic Sclerosis- Associated Interstitial Lung Disease (SSc-ILD) by Composite Physiologic Index (CPI) at Baseline
    Wells, A. U.
    Highland, K. B.
    Glaeser, S.
    Nunes, H.
    Song, J. W.
    Wuyts, W. A.
    Stock, C.
    Alves, M.
    Padilla, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
12345